Brand drug pricing has received increasing attention in the United States.Under pressure to reduce drug prices, the U.S. Department of Health and Human Services (HHS) on October 15, 2018 issued a "regulatory proposal" that any drug that is covered by Medicare or Medicaid, if priced at more than $35 per month, be added to the standard pricing information (list price) in television advertisements.It is also the first time that HHS has explicitly asked a pharmaceutical company operating in the United States to add drug price information to its television advertisements.
But the industry's opposition to President Trump's proposed bill argues that although the announcement of drug pricing is a measure of transparency, very few people pay the highest fees at their own expense.The Pharmaceutical Research and Manufacturers of America (PhRMA) recommends adding a website to a television advertisement.In this way, Lilly has launched a television advertisement for its diabetes drug Trulicity since December 2018 and announced plans to promote all of its drugs in the same manner by the end of February 2019.
Health care industry participants.146 feedback from physicians and consumers.The HHS will decide whether the proposal will be formally implemented based on feedback.On February 7, Johnson & Johnson announced that it would announce the pricing of its prescription drugs in television ads.Johnson & Johnson was the first pharmaceutical giant to respond to the HHS proposal and decide to give drug pricing information directly in television advertisements.
Scott White, head of marketing for J & J's North American pharmaceuticals business, said: "We will take the lead in publishing price information in TV ads starting with the anticoagulant Xarelto (rivaroxaban)."Starting in March 2019, Xarelto's commercial will add pricing and the general cost to consumers.At the same time, there will be information on the website of the drug insurance for consumers to understand the specific costs.
Johnson & Johnson stated in the statement: "Starting with the most prescribed drugs, we can better evaluate the acceptance of drug pricing and self-paid cost information in the general population. We will decide on the subsequent release scheme of drug TV advertisement based on the feedback from patients and consumers".
The United States has approximately 1 million prescriptions for Xarelto per month.Without health insurance, Xarelto's monthly patient out-of-pocket costs range from $450 to $540, with some variation between pharmacies.It may be wise to publish pricing directly, according to an article published last month by JAMA (doi: 10.1001/jamainternmed.(August 9, 2008) suggest that the release of the "co-payment program can reduce the patient's out-of-pocket costs to 0 US dollars" information can effectively alleviate the patient's inner resistance to high drug prices.
In fact, Johnson & Johnson, in its feedback to HHS, opposed extending this form of drug price disclosure to publications.Digital media or other media channels.J & J also called for allowing doctors to provide additional pricing information and new payment methods when introducing patients to drug prices.
1.FiercePharma.How to trump the Trump administration?For JampJ, it's putting list prices in ads before it's forced to
2.STAT. Trump administration says it will force drug makers to disclose prices in ads